

December 1, 2020

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: **512529**

Symbol: **SEQUENT**

Subject: Press Release – SeQuent announced launch of inhouse developed Halofusol® in EU

Dear Sir / Madam,

We enclose herewith a copy of Press Release that is being issued by the Company, in connection with the above-mentioned subject.

You are requested to take the same on record.

Thanking you.

Yours faithfully

For **Sequent Scientific Limited**



Krunal Shah

Company Secretary & Compliance Officer



Encl.: as above

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area,
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

SeQuent announced launch of inhouse developed Halofusol® in EU

Mumbai, December 1, 2020

SeQuent Scientific Limited (SeQuent), announced launch of Halofusol® 0.5 mg/ml Oral Solution for Calves in 19 European countries. The product had recently received approval from the European Medicines Agency (EMA) through its Spanish subsidiary Laboratorios Karizoo, S.A.

The product was developed at SeQuent's R&D centre at Barcelona, Spain & will be manufactured in Spain. The approval follows the recent approval of Tulathromycin, both of which were approved within 12 months of filing, reflecting of SeQuent's growing strength in product development for the regulated markets.

Halofusol® offers superior value for farmers with user-friendly and cost-effective drug delivery system.

Halofusol is an oral antiprotozoal solution for the prevention and reduction of diarrhoea in new-born calves, diagnosed with *Cryptosporidium parvum* and is a generic version of Halocur (Innovator: Merck Animal Health) with market size of ~€10Mn in EU. SeQuent is also planning to extend the launch to other geographies.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer Tel: +91 22 4111 4717
tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations Tel : +91 22 4215 0210
dpingle@christensenir.com

Abhishek Singhal

Investor Relations Consultants abhishek.s@sequent.in

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra, India CIN:

L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Websites: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.